<DOC>
	<DOCNO>NCT01297569</DOCNO>
	<brief_summary>This study design explore individualized treatment regime base achievement disease stability define personal optimal treatment interval ranibizumab patient visual impairment due diabetic macular edema .</brief_summary>
	<brief_title>Ranibizumab `` Treat Extend '' Diabetic Macular Edma</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment due focal diffuse macular edema center involvement Diabetes type 1 2 , HbA1c &lt; 12.0 % CRT = &gt; 250 Î¼m Active inflammation infection Uncontrolled glaucoma Iris neovascularization , active proliferative retinopathy vitreomacular traction Prior laser photocoagulation accord define timeline History stroke , uncontrolled hypertension Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>Diabetic eye disease</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Lucentis</keyword>
</DOC>